Literature DB >> 8427037

Murine model for evaluation of protective immunity to influenza virus.

M Novak1, Z Moldoveanu, D P Schafer, J Mestecky, R W Compans.   

Abstract

We have characterized a murine model as an inexpensive, readily available and sensitive animal model for the evaluation of protective immune responses induced by various routes of administration of influenza A vaccine preparations. Using a non-mouse-adapted human influenza virus to infect unanaesthetized animals intranasally, we established that the optimum dose for infection of Balb/c mice was 10(4) plaque forming units of virus and that the optimum sampling time for measurement of virus yields in the organs of the respiratory tract was 72 h after challenge. We found that the infection was initiated in the nose and progressed by descending into the trachea and lungs over a period of days. Evaluation of protection against infection clearly showed that the tissues of the mouse respiratory tract were completely protected after administration of whole killed virus intranasally and partly protected when virus was administered subcutaneously. The protection correlated with the level of virus-specific IgA antibodies in saliva.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8427037     DOI: 10.1016/0264-410x(93)90339-y

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  35 in total

Review 1.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

2.  Mucosally induced immunoglobulin E-associated inflammation in the respiratory tract.

Authors:  J W Simecka; R J Jackson; H Kiyono; J R McGhee
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

3.  Influenza A virus infection of primary differentiated airway epithelial cell cultures derived from Syrian golden hamsters.

Authors:  Celeste M Newby; Regina K Rowe; Andrew Pekosz
Journal:  Virology       Date:  2006-07-31       Impact factor: 3.616

4.  Specific-pathogen-free pigs as an animal model for studying Chlamydia trachomatis genital infection.

Authors:  Daisy Vanrompay; Thi Q T Hoang; Liselotte De Vos; Kristel Verminnen; Taher Harkinezhad; Koen Chiers; Servaas A Morré; Eric Cox
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

5.  Anti-influenza virus activities of 4-substituted 2,4-dioxobutanoic acid inhibitors.

Authors:  J C Hastings; H Selnick; B Wolanski; J E Tomassini
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

6.  Stability of whole inactivated influenza virus vaccine during coating onto metal microneedles.

Authors:  Hyo-Jick Choi; Brian J Bondy; Dae-Goon Yoo; Richard W Compans; Sang-Moo Kang; Mark R Prausnitz
Journal:  J Control Release       Date:  2012-12-13       Impact factor: 9.776

7.  Kinetics of immune responses to influenza virus-like particles and dose-dependence of protection with a single vaccination.

Authors:  Fu Shi Quan; Dae-Goon Yoo; Jae-Min Song; John D Clements; Richard W Compans; Sang-Moo Kang
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

8.  Adjuvanted influenza vaccine administered intradermally elicits robust long-term immune responses that confer protection from lethal challenge.

Authors:  Maria del P Martin; Shaguna Seth; Dimitrios G Koutsonanos; Joshy Jacob; Richard W Compans; Ioanna Skountzou
Journal:  PLoS One       Date:  2010-05-28       Impact factor: 3.240

9.  Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection.

Authors:  Bao-Zhong Wang; Rui Xu; Fu-Shi Quan; Sang-Moo Kang; Li Wang; Richard W Compans
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

10.  Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin.

Authors:  Fu-Shi Quan; Yeu-Chun Kim; Dae-Goon Yoo; Richard W Compans; Mark R Prausnitz; Sang-Moo Kang
Journal:  PLoS One       Date:  2009-09-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.